Study details
Enrolling now
Lenrispodun Trial for Parkinson's Disease
Intra-Cellular Therapies, Inc.
NCT IDNCT05766813ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
132
Study length
about 2.6 years
Ages
40+
Locations
31 sites in AZ, CA, FL +11
About this study
This trial is testing Lenrispodun as an add-on treatment for people with Parkinson's disease who have motor fluctuations. Participants will be randomly assigned to receive either Lenrispodun or a placebo (inactive pill). It lasts 963 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Lenrispodun
- 2.Take Placebo
PhasePhase 2
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low6%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Secondary: Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
Body systems
Neurology